Fig. 1
EVs-associated LGALS3BP levels correlate with metastatatic lesions and increase accordingly over time in a pseudometastatic model of human neuroblastoma. (A) Representative scheme of pseudometastatic model: human neuroblastoma SKNAS cells were tail-vein injected in NSG mice and blood was collected after 7 (n = 2), 14 (n = 3), 21 (n = 3), and 28 (n = 2) days. (B) EVs-associated LGALS3BP levels detected in ELISA (pg/mL) per µg of EVs isolated from mouse serum after 7 (n = 2), 14 (n = 3), 21 (n = 3), or 28 (n = 2) days. Tumor free mice (n = 2) were considered as controls. (C) Immunohistochemistry staining with hematoxylin/eosin for metastatic lesions and LGALS3BP levels in metastatic lesions over time. Scale bar: 250 μm. Number of metastases detected in (D) liver, (E) lung, and (F) kidney of NSG mice after 7 (n = 2), 14 (n = 3), 21 (n = 3), and 28 (n = 2) days